Vbi Vaccines Inc CS (VBIV)

$2.61 0.08 (3.16%)

19:59 EDT VBIV Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap 167.25M

PE Ratio -

EPS -

Volume (Avg. Vol.) 4.15M

Day's Range 2.48 - 2.65

52-Week Range 0.53 - 6.93

Dividend & Yield N/A (N/A)

VBIV Stock Predictions, Articles, and Vbi Vaccines Inc CS News

From InvestorPlace
From the Web

7 Short-Term Stocks to Make a Quick Buck

By Josh Enomoto, InvestorPlace Contributor Oct 16, 2020

It wasn’t just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.

While Risks Remain, VBI Vaccines Stock Is a Buy at Today’s Prices

By Thomas Niel Feb 5, 2020

Sci-B-Vac's success will make or break VBIV stock. But the shares' recent pullback may have created a great buying opportunity.

5 Stocks Under $5 With Colossal Growth Prospects

By Maya Sasson, Writer, TipRanks Jan 31, 2020

While some argue you get what you pay for, others say that stocks trading at low levels can represent compelling opportunities.

Is It Time to Go Long on VBIV Stock?

By Chris Markoch Jan 30, 2020

As a speculative pharmaceutical investment, VBIV stock is not for the faint of heart. However, the underlying business suggests some rationale for longer-term optimism.

VBI Vaccines News: VBIV Stock Skyrockets 17% on Clinical Trial Success

By William White, InvestorPlace Writer Jan 13, 2020

VBI Vaccines (VBIV) news for Monday about results from a recent clinical trial of a hepatitis B vaccine have VBI stock soaring.

5 Stocks to Buy Based on Insider Buying

By Mark Putrino, CMT Oct 8, 2019

These are five stocks to consider buying because of significant insider buying activity. Insiders only buy for one reason: to make money.

3 Pivotal Drug Trials to Watch for Explosive Potential

By Samuel Rae, InvestorPlace Contributor Jun 29, 2017

Here's a look at three biotech stocks that have at least one treatment prepped to enter pivotal clinical trials soon.

Better Coronavirus Stock: Inovio Pharmaceuticals or VBI Vaccines?

From The Motley Fool Oct 18, 2020

Neither biotech is in the front of the pack in developing a COVID-19 vaccine.

Interesting VBIV Put And Call Options For December 18th

From Market News Video Oct 16, 2020

Investors in VBI Vaccines Inc (VBIV) saw new options begin trading this week, for the December 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the VBIV options chain for the new December 18th contracts and identified one put and one call contract of particular interest.

VBI Vaccines, Inc. (VBIV) Gains But Lags Market: What You Should Know

From Zacks Investment Research Oct 9, 2020

In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.95, marking a +0.68% move from the previous day.

Why These Coronavirus Vaccine Stocks Crashed in September

From The Motley Fool Oct 8, 2020

In the race for a vaccine, a pause in progress sets you back.

Unusual Options Activity Insight: VBI Vaccines

From Benzinga Sep 3, 2020

On Thursday, shares of VBI Vaccines (NASDAQ: VBIV) saw unusual options activity. After the option alert, the stock price moved down to $3.52. Sentiment: BEARISH Option Type:...

EmergingGrowth.com Reports on Why VBI Vaccines (NASDAQ: VBIV) Could Be a Contrarian Investor’s Dream

From EIN Presswire Sep 30, 2020

With few appreciating the science behind VBIV stock, this could be an undervalued winner

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy